Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EQT offers to buy Karo Pharma for $654m
Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the
Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the
In addition, there is an ongoing earn-out payment based as a percentage of net sales over a 10-year period. Under the terms of the asset purchase, license and
Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks). Secondary
The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg in comparison to placebo. It was carried out
A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA, Darmstadt, Germany’s
An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. The agreement provides
In the pharmaceutical industry, clinical-trial data is of paramount importance for drug development, and must be backed up and protected against any potential mishaps. Therefore, a Hybrid Cloud
The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic
Cerevel Therapeutics has secured $350m funding from funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences. They have also committed to provide further capital if
RPD designation for progeria and progeroid laminopathies enables priority review voucher (PRV) eligibility upon FDA approval of a rare pediatric disease product application for lonafarnib for these ultra-rare